The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Human Leishmaniasis: Clinical, Diagnostic, and Chemotherapeutic Developments in the Last 10 Years
Abstract
The current interest in leishmaniasis stems from the importance of this disease with respect to travel medicine, veterans of Operation Desert Storm, humanitarian concerns, and infection with human immunodeficiency virus. Herein, I review aspects of leishmaniasis that are of practical value to practitioners, including presentation, diagnosis, and chemotherapy; I will emphasize advances in chemotherapy over the last 10 years. Amphotericin B and its new lipid formulations are now competitive with pentavalent antimony as primary therapy for visceral leishmaniasis. Pentamidine, paromomycin, and adjunctive therapy with interferon-gamma are secondary regimens for the treatment of this condition. High-dose long-term regimens of antimony have been shown to be highly effective for the treatment of cutaneous leishmaniasis. Preliminary evidence of efficacy has been observed with short courses of pentamidine for the treatment of Leishmania braziliensis complex disease and topical paromomycin/methylbenzethonium chloride for the treatment of Leishmania major disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Perspectives on a Subclinical Form of Visceral Leishmaniasis
Badaro, R., Jones, T. C., Carvalho, E. M., Sampaio, D., Reed, S. G., Barral, A., Teixeira, R., & Johnson, W. D. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/154.6.1003 · Cited by 480
Interleukin 10 production correlates with pathology in human Leishmania donovani infections.
Ghalib, H. W., Piuvezam, M. R., Skeiky, Y. A., Siddig, M., Hashim, F. A., el-Hassan, A. M., Russo, D. M., & Reed, S. G. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116570 · Cited by 434
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Chemotherapy for Leishmaniasis: Biochemical Mechanisms, Clinical Efficacy, and Future Strategies
Berman, J. D. (1988) · Clinical Infectious Diseases · doi:10.1093/clinids/10.3.560 · Cited by 380
Self-citationVisceral Infection Caused by Leishmania tropica in Veterans of Operation Desert Storm
Magill, A. J., Grogl, M., Gasser, R. A., Sun, W., & Oster, C. N. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305133281904 · Cited by 369
Cytokine patterns in the pathogenesis of human leishmaniasis.
Pirmez, C., Yamamura, M., Uyemura, K., Paes-Oliveira, M., Conceição-Silva, F., & Modlin, R. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116341 · Cited by 364
Estimation of population at risk of infection and number of cases of Leishmaniasis
Ashford, R. W., Desjeux, P., & deRaadt, P. (1992) · Parasitology Today · doi:10.1016/0169-4758(92)90249-2 · Cited by 356
Karp, C. L., el-Safi, S. H., Wynn, T. A., Satti, M. M., Kordofani, A. M., Hashim, F. A., Hag-Ali, M., Neva, F. A., Nutman, T. B., & Sacks, D. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116372 · Cited by 340
Treatment of Visceral Leishmaniasis with Pentavalent Antimony and Interferon Gamma
Badaro, R., Falcoff, E., Badaro, F. S., Carvalho, E. M., Pedral-Sampaio, D., Barral, A., Carvalho, J. S., Barral-Netto, M., Brandely, M., Silva, L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220104 · Cited by 310
An analysis of T cell responsiveness in Indian kala-azar.
Sacks, D. L., Lal, S. L., Shrivastava, S. N., Blackwell, J., & Neva, F. A. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.3.908 · Cited by 251
Cited by
Reithinger, R., Dujardin, J.-C., Louzir, H., Pirmez, C., Alexander, B., & Brooker, S. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70209-8 · Cited by 1,334
Herwaldt, B. L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10178-2 · Cited by 1,229
Oral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 779
Self-citationSundar, S., More, D. K., Singh, M. K., Singh, V. P., Sharma, S., Makharia, A., Kumar, P. C. K., & Murray, H. W. (2000) · Clinical Infectious Diseases · doi:10.1086/318121 · Cited by 664
Blood Groups in Infection and Host Susceptibility
Cooling, L. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-14 · Cited by 632
A Review of Leishmaniasis: Current Knowledge and Future Directions
Mann, S., Frasca, K., Scherrer, S., Henao-Martínez, A. F., Newman, S., Ramanan, P., & Suarez, J. A. (2021) · Current Tropical Medicine Reports · doi:10.1007/s40475-021-00232-7 · Cited by 536
Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis
Jha, T. K., Sundar, S., Thakur, C. P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., & Berman, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412403 · Cited by 468
Self-citationAlvar, J., Cañavate, C., Molina, R., Moreno, J., & Nieto, J. (2004) · Advances in Parasitology · doi:10.1016/s0065-308x(04)57001-x · Cited by 431
Leishmania infections: Molecular targets and diagnosis
Akhoundi, M., Downing, T., Votýpka, J., Kuhls, K., Lukeš, J., Cannet, A., Ravel, C., Marty, P., Delaunay, P., Kasbari, M., et al. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.11.012 · Cited by 363
Fluconazole for the Treatment of Cutaneous Leishmaniasis Caused by Leishmania major
Alrajhi, A. A., Ibrahim, E. A., De Vol, E. B., Khairat, M., Faris, R. M., & Maguire, J. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011882 · Cited by 328
Sato, S., St‐Pierre, C., Bhaumik, P., & Nieminen, J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00790.x · Cited by 299
Roberts, C. W., McLeod, R., Rice, D. W., Ginger, M., Chance, M. L., & Goad, L. J. (2003) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(02)00280-3 · Cited by 296
Meyerhoff, A. (1999) · Clinical Infectious Diseases · doi:10.1086/515085 · Cited by 295
Challenges and new discoveries in the treatment of leishmaniasis
Singh, S., & Sivakumar, R. (2004) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-004-0348-9 · Cited by 293
Leishmania requires Rab7-mediated degradation of endocytosed hemoglobin for their growth
Patel, N., Singh, S. B., Basu, S. K., & Mukhopadhyay, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800404105 · Cited by 56
Metadata
- Authors
- Berman, J. D.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-04-01
- Volume
- 24
- Issue
- 4
- Pages
- 684-703
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2168946125
- Cited by
- 806
- References
- 28
- FWCI
- 43.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.